EUVIMEDEUVIMED entdecken
Systematische Übersicht

Diagnostic Performance of FAPI PET in Patients with Breast Cancer: A Systematic Review

Lisa E H W Duijx, Melissa Lenaerts, Marjolein L Smidt, Sofia C Vaz, Philipp Backhaus, Matthias Bauwens, Felix M Mottaghy, Joachim E Wildberger, Thiemo J A van Nijnatten

Journal of Nuclear Medicine · 2026-08 · 67 (8) · 1201-1208

DOI: 10.2967/jnumed.126.272191 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 14.05.2026. Verfasst von Lisa E H W Duijx und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands; lisa.duijx@mumc.nl. Hauptthemen laut MEDLINE: Breast Neoplasms, Positron-Emission Tomography. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We evaluated the diagnostic performance of fibroblast activation protein inhibitor (FAPI) PET for lesion detection at breast cancer diagnosis and response assessment after neoadjuvant chemoimmunotherapy (NAC) and compared these findings with those from [18F]FDG PET or histopathology after the completion of NAC.

Methods

A systematic search across PubMed, EMBASE, Web of Science, and Cochrane Trial databases up to January 12, 2026, was conducted. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies version 2 tool. Extracted data included SUVmax, tumor-to-background ratio, and lesion detection in studies comparing FAPI PET with [18F]FDG PET. For studies comparing FAPI PET with histopathology, diagnostic performance parameters were obtained. Data on FAPI uptake, stratified by histology type, molecular subtype, and tumor grade, were extracted.

Results

The literature search yielded 3662 studies, 13 of which were included in this review. Of these, 10 compared FAPI PET with [18F]FDG PET and 3 compared FAPI PET findings with those of histopathology after the completion of NAC. The reported mean SUVmax range was 6.5-17.1 versus 3.9-8.3 for primary tumors, 5.1-17.1 versus 1.2-10.3 for axillary lymph node metastases, and 4.9-21.7 versus 1.7-8.1 for distant metastases on FAPI PET versus [18F]FDG PET, respectively. FAPI PET detected more lesions compared with [18F]FDG PET in all evaluated anatomic sites. In post-NAC response assessment of the breast tumor, FAPI PET reported a sensitivity and specificity of 73%-100% and 71%-100%, respectively. Lower FAPI uptake was observed in low-grade, luminal A tumors and in those with lobular histology.

Conclusion

FAPI PET demonstrated increased lesion detection compared with [18F]FDG PET at the time of breast cancer diagnosis and demonstrated considerable diagnostic performance for assessing response evaluation after NAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPositron-Emission TomographyHumansFemaleFibroblast Activation Protein AlphaFluorodeoxyglucose F18

Stichwörter der Autor:innen

FAPIPETbreast cancerclinical subtypesdiagnostic performance

Substanzen

Fibroblast Activation Protein AlphaFluorodeoxyglucose F18

Autor:innen und Institutionen

  • Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands; lisa.duijx@mumc.nl.
  • GROW-Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.
  • Department of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands.
  • Department of Nuclear Medicine-Radiopharmacology, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
  • Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Nuclear Medicine, University Hospital Münster, Münster, Germany.

Zitieren

APA

Duijx, L. E. H. W., Lenaerts, M., Smidt, M. L., Vaz, S. C., Backhaus, P., Bauwens, M., Mottaghy, F. M., Wildberger, J. E., & van Nijnatten, T. J. A. (2026). Diagnostic Performance of FAPI PET in Patients with Breast Cancer: A Systematic Review. Journal of Nuclear Medicine, 67(8), 1201-1208. https://doi.org/10.2967/jnumed.126.272191

Vancouver

Duijx LEHW, Lenaerts M, Smidt ML, Vaz SC, Backhaus P, Bauwens M, et al. Diagnostic Performance of FAPI PET in Patients with Breast Cancer: A Systematic Review. Journal of Nuclear Medicine. 2026;67(8):1201-1208. doi:10.2967/jnumed.126.272191

BibTeX
@article{Duijx2026,
  author = {Duijx, Lisa E H W and Lenaerts, Melissa and Smidt, Marjolein L and Vaz, Sofia C and Backhaus, Philipp and Bauwens, Matthias and Mottaghy, Felix M and Wildberger, Joachim E and van Nijnatten, Thiemo J A},
  title = {Diagnostic Performance of FAPI PET in Patients with Breast Cancer: A Systematic Review},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  volume = {67},
  number = {8},
  pages = {1201--1208},
  doi = {10.2967/jnumed.126.272191}
}
Kostenlos starten →